Bayesian randomized clinical trials: From fixed to adaptive design.

Area of Science:

• Biostatistics
• Clinical Trial Design
• Pharmaceutical Research

Background:

• Randomized controlled trials (RCTs) are standard for phase III studies, often employing group sequential methods with alpha-spending functions to control Type I error rates.
• Frequentist approaches dominate phase III clinical trial design, but Bayesian methods offer complementary strategies.

Purpose of the Study:

• To explore Bayesian randomized designs as a complement to frequentist methods in phase III clinical trials.
• To compare Bayesian and frequentist approaches through numerical studies, focusing on fixed and adaptive designs.

Main Methods:

• Utilizing Bayesian decision-theoretic approaches, including posterior probability and Bayes factor frameworks for hypothesis testing.
• Employing Bayesian group sequential designs based on backward induction.
• Comparing Bayesian and frequentist methods through numerical simulations across various designs.

Main Results:

• Bayesian methods provide advantages such as posterior predictive probability for convenient trial monitoring and real-time updates.
• The Bayesian decision-theoretic framework allows for realistic cost-benefit analysis and direct links to practical decision-making.
• Bayesian approaches facilitate hierarchical modeling and the use of informative priors for enhanced data utilization.

Conclusions:

• Bayesian randomized designs offer a valuable alternative and complement to traditional frequentist methods in phase III clinical trials.
• The flexibility and enhanced data integration capabilities of Bayesian methods support more robust drug development processes.
• Further exploration of Bayesian designs, from fixed to adaptive, is warranted for optimizing clinical trial efficiency and decision-making.